A 62-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with hemoglobin 8.5 g/dL, normal iron studies, and low reticulocyte count. He has no active bleeding or hemolysis. What is the drug of choice for his anemia?

Question

Accepted Answer

B. Erythropoiesis-stimulating agent (ESA) – Epoetin alfa. ## Diagnosis: Anemia of Chronic Kidney Disease (CKD) ### Pathophysiology Chronic kidney disease causes anemia primarily due to decreased erythropoietin (EPO) production by the kidneys. The low reticulocyte count and normal iron studies exclude iron deficiency and hemolysis. ### Drug of Choice: Erythropoiesis-Stimulating Agents (ESAs) **Key Point:** ESAs (epoetin alfa, darbepoetin alfa) are the first-line pharmacological treatment for anemia of CKD. They stimulate erythropoiesis by mimicking endogenous EPO. **High-Yield:** ESAs are indicated when hemoglobin is <10 g/dL in CKD patients with low reticulocyte count and normal iron stores. Target hemoglobin is typically 10–11 g/dL (avoid overcorrection due to thrombotic risk). ### Treatment Algorithm for CKD Anemia ```mermaid flowchart TD A[CKD patient with anemia] --> B[Assess iron stores] B -->|Iron deficient| C[Correct iron first] B -->|Iron replete| D[Check reticulocyte count] D -->|Low| E[ESA indicated] D -->|High| F[Evaluate for bleeding/hemolysis] E --> G[Epoetin alfa or Darbepoetin] G --> H[Target Hb 10-11 g/dL] ``` ### Comparison of Anemia Treatments in CKD | Agent | Mechanism | Indication | Efficacy | |-------|-----------|-----------|----------| | **ESA (Epoetin/Darbepoetin)** | EPO mimetic | First-line for low EPO | 70–80% response | | Iron supplementation | Substrate for Hb synthesis | Iron deficiency only | Prerequisite | | Vitamin B12/Folate | Cofactors for RBC synthesis | Deficiency only | Adjunctive | | Blood transfusion | Direct RBC replacement | Emergency/Hb <7 g/dL | Temporary | **Clinical Pearl:** Iron stores must be adequate (serum ferritin >100 ng/mL, transferrin saturation >20%) before starting ESAs. Many CKD patients require concurrent IV iron. **Warning:** Overcorrection of anemia with ESAs increases risk of thrombotic events (MI, stroke, DVT). Current guidelines recommend target Hb of 10–11 g/dL, not normalization. **Mnemonic:** **ESA-CKD** = Erythropoiesis-Stimulating Agent for Chronic Kidney Disease anemia.

Answer

A. Folic acid and vitamin B12

Answer

C. Blood transfusion

Answer

D. Oral iron supplementation

A 62-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with hemoglobin 8.5 g/dL, normal iron studies, and low reticulocyte count. He has no active bleeding or hemolysis. What is the drug of choice for his anemia?

Explanation

Diagnosis: Anemia of Chronic Kidney Disease (CKD)

Pathophysiology

Drug of Choice: Erythropoiesis-Stimulating Agents (ESAs)

Treatment Algorithm for CKD Anemia

Comparison of Anemia Treatments in CKD

Practice similar questions

Join our NEET PG community

Agent	Mechanism	Indication	Efficacy
ESA (Epoetin/Darbepoetin)	EPO mimetic	First-line for low EPO	70–80% response
Iron supplementation	Substrate for Hb synthesis	Iron deficiency only	Prerequisite
Vitamin B12/Folate	Cofactors for RBC synthesis	Deficiency only	Adjunctive
Blood transfusion	Direct RBC replacement	Emergency/Hb <7 g/dL	Temporary